دورية أكاديمية
أعرض في EDS

Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy.
المؤلفون: Edwards C; University of Maryland Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States., Carey ST; University of Maryland Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States., Jewell CM; University of Maryland Fischell Department of Bioengineering, University of Maryland, College Park, Maryland 20742, United States.; United States Department of Veterans Affairs, VA Maryland Health Care System, Baltimore, Maryland 21201, United States.; Robert E. Fischell Institute for Biomedical Devices, College Park, Maryland 20742, United States.; Department of Microbiology and Immunology, University of Maryland Medical School, Baltimore, Maryland 21201, United States.; Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland 21201, United States.
المصدر: ACS applied bio materials [ACS Appl Bio Mater] 2023 Jun 19; Vol. 6 (6), pp. 2017-2028. Date of Electronic Publication: 2023 Apr 17.
نوع المنشور: Journal Article; Review; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: ACS Publications Country of Publication: United States NLM ID: 101729147 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2576-6422 (Electronic) Linking ISSN: 25766422 NLM ISO Abbreviation: ACS Appl Bio Mater Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : ACS Publications, [2018]-
مواضيع طبية MeSH: Biocompatible Materials*/therapeutic use , Biocompatible Materials*/chemistry , Neoplasms*/drug therapy, Humans ; Immunotherapy ; Antigens ; Signal Transduction
مستخلص: Immunotherapies are an evolving treatment paradigm for addressing cancer, autoimmunity, and infection. While exciting, most of the existing therapies are limited by their specificity─unable to differentiate between healthy and diseased cells at an antigen-specific level. Biomaterials are a powerful tool that enable the development of next-generation immunotherapies due to their tunable synthesis properties. Our lab harnesses biomaterials as tools to study antigen-specific immunity and as technologies to enable new therapeutic vaccines and immunotherapies to combat cancer, autoimmunity, and infections. Our efforts have spanned the study of intrinsic immune profiles of biomaterials, development of novel nanotechnologies assembled entirely from immune cues, manipulation of innate immune signaling, and advanced technologies to direct and control specialized immune niches such as skin and lymph nodes.
References: ACS Biomater Sci Eng. 2020 Feb 10;6(2):759-778. (PMID: 33313391)
Adv Funct Mater. 2020 Nov 25;30(48):. (PMID: 33692662)
J Dermatol Sci. 2015 Feb;77(2):85-92. (PMID: 25301671)
J Biomed Mater Res A. 2017 Apr;105(4):1219-1229. (PMID: 27977902)
Acta Biomater. 2016 Mar 01;32:24-34. (PMID: 26708710)
J Invest Dermatol. 2001 Feb;116(2):313-8. (PMID: 11180009)
Cancers (Basel). 2020 May 04;12(5):. (PMID: 32375310)
Nat Mater. 2018 Jun;17(6):484-498. (PMID: 29784994)
Adv Sci (Weinh). 2022 Nov 14;:e2202393. (PMID: 36373708)
ACS Biomater Sci Eng. 2015 Dec 14;1(12):1200-1205. (PMID: 26689147)
Infect Immun. 2018 Aug 22;86(9):. (PMID: 29986891)
Front Immunol. 2022 Mar 14;13:843355. (PMID: 35359943)
N Engl J Med. 2017 Feb 16;376(7):697-699. (PMID: 28199812)
J Vis Exp. 2014 Jan 02;(83):e50984. (PMID: 24430972)
ACS Biomater Sci Eng. 2021 May 10;7(5):1854-1862. (PMID: 33616392)
J Biomed Mater Res A. 2017 Nov;105(11):2977-2985. (PMID: 28646511)
Transplantation. 2019 Oct;103(10):2075-2089. (PMID: 31343575)
Nano Lett. 2021 May 12;21(9):3762-3771. (PMID: 33881872)
J Allergy Clin Immunol. 2012 May;129(5):1290-6. (PMID: 22464647)
Small. 2018 Sep;14(38):e1802202. (PMID: 30146797)
Nano Today. 2019 Aug;27:73-98. (PMID: 32292488)
ACS Biomater Sci Eng. 2017 Feb 13;3(2):195-205. (PMID: 28286864)
ACS Appl Mater Interfaces. 2016 Jul 27;8(29):18722-31. (PMID: 27380137)
ACS Nano. 2021 Mar 23;15(3):4305-4320. (PMID: 33645967)
Adv Funct Mater. 2017 Jun 13;27(22):. (PMID: 29503604)
Bioeng Transl Med. 2017 May 16;2(2):139-155. (PMID: 28932817)
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15745-50. (PMID: 21896725)
Cell Mol Bioeng. 2016;9:418-432. (PMID: 27547269)
Cell Rep. 2016 Sep 13;16(11):2940-2952. (PMID: 27626664)
Immunol Rev. 2019 Nov;292(1):9-23. (PMID: 31538349)
Curr Opin Organ Transplant. 2018 Feb;23(1):73-82. (PMID: 29189412)
J Invest Dermatol. 2014 Apr;134(4):965-974. (PMID: 24352044)
Biomater Sci. 2022 Aug 9;10(16):4612-4626. (PMID: 35796247)
Adv Drug Deliv Rev. 2017 May 15;114:60-78. (PMID: 28392305)
Acta Biomater. 2018 Mar 1;68:168-177. (PMID: 29292166)
J Control Release. 2017 Oct 10;263:151-161. (PMID: 28257991)
AAPS J. 2017 Jul;19(4):1175-1185. (PMID: 28484962)
Biotechnol Bioeng. 2017 Feb;114(2):423-431. (PMID: 27567213)
Biomater Sci. 2019 Feb 26;7(3):798-808. (PMID: 30656310)
Cancer Lett. 2019 Sep 10;459:192-203. (PMID: 31185250)
Front Immunol. 2021 Jan 06;11:613830. (PMID: 33488621)
Adv Ther (Weinh). 2019 Jun;2(6):. (PMID: 31236439)
ACS Cent Sci. 2018 May 23;4(5):567-581. (PMID: 29806003)
Lancet Diabetes Endocrinol. 2023 Feb;11(2):76-77. (PMID: 36623518)
Adv Sci (Weinh). 2023 Mar;10(8):e2205105. (PMID: 36638260)
Bioeng Transl Med. 2019 Sep 18;5(1):e10142. (PMID: 31989033)
Trends Immunol. 2018 Feb;39(2):135-150. (PMID: 29249461)
Drug Deliv Transl Res. 2021 Dec;11(6):2468-2481. (PMID: 34611846)
Curr Opin Biotechnol. 2019 Dec;60:138-145. (PMID: 30831487)
Biomater Sci. 2017 Dec 19;6(1):115-124. (PMID: 29177268)
Oncotarget. 2016 Mar 29;7(13):15421-43. (PMID: 26871948)
ACS Nano. 2016 Oct 25;10(10):9334-9345. (PMID: 27579996)
Front Immunol. 2017 Nov 29;8:1676. (PMID: 29238347)
Front Immunol. 2019 Mar 06;10:360. (PMID: 30894857)
Nat Commun. 2023 Feb 8;14(1):681. (PMID: 36755035)
Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):537-43. (PMID: 19680119)
J Control Release. 2015 Jul 28;210:169-78. (PMID: 26002150)
Adv Healthc Mater. 2019 Feb;8(4):e1801419. (PMID: 30605264)
Acc Chem Res. 2020 Nov 17;53(11):2534-2545. (PMID: 33074649)
معلومات مُعتمدة: I01 BX003690 United States BX BLRD VA; R01 AI169686 United States AI NIAID NIH HHS; R01 EB027143 United States EB NIBIB NIH HHS; R01 AI144667 United States AI NIAID NIH HHS; T32 CA154274 United States CA NCI NIH HHS; T32 AI089621 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: autoimmunity; biomaterials; immune engineering; immunology; nanotechnology; vaccine
المشرفين على المادة: 0 (Biocompatible Materials)
0 (Antigens)
تواريخ الأحداث: Date Created: 20230417 Date Completed: 20230620 Latest Revision: 20240620
رمز التحديث: 20240620
مُعرف محوري في PubMed: PMC10330265
DOI: 10.1021/acsabm.3c00136
PMID: 37068126
قاعدة البيانات: MEDLINE
الوصف
تدمد:2576-6422
DOI:10.1021/acsabm.3c00136